Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Polyphor AG, CH0106213793

Polyphor AG, CH0106213793

05.01.2021 - 07:33:44

EQS-Adhoc: Polyphor to take part in panel discussion on novel oncology targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Allschwil, Switzerland, January 5, 2021

Polyphor to take part in panel discussion on novel oncology targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Polyphor AG (SIX: POLN) announced today that G?khan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Thursday, January 7 from 8:00AM Eastern Standard Time.

The panel is entitled "Separating the Wheat from the Chaff: Most Promising Novel Oncology Targets in Development". Investors can pre-register for the event here.

Polyphor is currently conducting the Phase III FORTRESS trial with balixafortide, a potent and selective CXCR4 antagonist, in patients with HER2 negative, locally recurrent or metastatic breast cancer. Data on the key primary endpoint of FORTRESS, progression free survival (PFS) in the overall population, is planned for Q4 2021. An analysis of the objective response rate (ORR) in eligible patients in third and later lines of chemotherapy is planned for Q2 2021.For further information please contact:

For Investors:

Hernan Levett Chief Financial Officer Polyphor Ltd. +41 61 567 16 00IR@polyphor.com Mary-Ann Chang LifeSci Advisors Tel: +44 7483 284 853mchang@lifesciadvisors.com ?

For Media: Bernhard Schmid LifeSci Advisors +41 44 447 12 21bschmid@lifesciadvisors.com

About Polyphor Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing first-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

End of ad hoc announcement Language: English Company: Polyphor AG Hegenheimermattweg 125 4123 Allschwil

Switzerland Phone: +41 61 567 1600 Fax: +41 61 567 1601 E-mail: info@polyphor.com Internet: www.polyphor.com ISIN: CH0106213793 Valor: POLN Listed: SIX Swiss Exchange EQS News ID: 1158405 ? End of Announcement EQS Group News Service


@ dgap.de